Lane, Michael
Polydefkis, Michael http://orcid.org/0000-0002-7584-7447
Funding for this research was provided by:
AstraZeneca
Article History
Received: 17 June 2024
Accepted: 9 August 2024
First Online: 6 September 2024
Declarations
:
: Michael Lane has nothing to disclose. Michael Polydefkis has received consulting fees for Alnylam, AstraZeneca and Intellia, and was a principal investigator for the NEURO-TTRtrial.
: This article does not contain any new studies with human participants or animals performed by any of the authors.